“Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s258. https://doi.org/10.25251/skin.7.supp.258.